ангиотензин-II 用于治疗双侧 Agenesis 的婴儿耐阻性低血压
Sheila Razdan1, Alexis S Davis1, George Tidmarsh1
1Division of Neonatal and Developmental Medicine.
Pediatrics
|December 15, 2023
概括
出生双侧衰老对婴儿构成风险. ангиотензин-II 在早产婴儿中有效治疗耐火性低血压,这可能为这种情况提供了一个新的治疗选择.
科学领域:
- 新生儿科学 新生儿科学
- 儿科脏病学 儿科脏病学
- 关键护理医学 关键护理医学
背景情况:
- 先天性双侧生代 (CBRA) 对婴儿具有重大风险,包括严重的低血压.
- 这些婴儿的耐阻性低血压可能会危及生命,并且很难用传统的血管压缩剂来控制.
研究的目的:
- 评估合成 ангиотензин-II 在治疗 CBRA 的早产婴儿中耐性低血压的疗效.
- 评估新生儿重症监护室 (NICU) 设置中的血管压缩剂 ангиотензин-II 的安全性和有效性.
主要方法:
- 一个病例报告详细介绍了合成血管新生素-II给诊断为CBRA的早产婴儿,并经历了难治性低血压.
- 监测婴儿的血液动力学状况和在血管素II治疗期间对其他血管压缩剂的需求.
主要成果:
- 婴儿的耐药性低血压在启动血管素II治疗后48小时内消失.
- 婴儿成功地戒除了其他血管压缩剂,随后从医院出院.
结论:
- 合成 ангиотензин-II 可能是一个有价值的治疗药物,用于管理与先天双侧衰老的婴儿的耐火性低血压.
- 这一案例凸显了血管新生素-II在具有挑战性的新生儿重症监护场景中的潜在效用.
相关概念视频
Antihypertensive Drugs: Direct Renin Inhibitors
632
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
632
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
Antihypertensive Drugs: Angiotensin II Receptor Blockers
743
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
743
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
648
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
648
Hormonal Regulation
33.2K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
33.2K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
170
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
170


